PRESS RELEASE
May23, 2022
Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that the results from the randomized controlled clinical trial of Tesomet for weight loss in patients with hypothalamic obesity has been published in the peer-reviewed scientific journal European Journal of Endocrinology. The conclusion is that the results are encouraging and support the continued investigation of Tesomet for the treatment of acquired hypothalamic obesity.
Professor Ulla Feldt-Rasmussen, M.D., DMSc., Department of Medical Endocrinology and Metabolism, Rigshospitalet Copenhagen University Hospital and Principal Investigator on the Phase 2 study stated, "Patients with hypothalamic obesity are faced with severe and debilitating overweight for which there is no approved treatments. I am highly encouraged by the study results, and I believe that Tesomet may become a valuable treatment of this rare disease, including management of the key characteristics of the disease such as: persistent hunger, loss of appetite control, uncontrollable weight gain and metabolic dysfunction. Equally important is the favorable safety and tolerability profile of Tesomet. These promising results warrant further studies and I look forward to the continued development of Tesomet as a potential first treatment to improve outcomes for patients with hypothalamic obesity".
The article in European Journal of Endocrinology) provides a description of the clinical trial and the obtained results.
The data was reviewed in an oral presentation on May 22th 2022 at the European Congress of Endocrinology in Milano by co-author Marianne Klose, M.D. Department of Medical Endocrinology and Metabolism, Rigshospitalet Copenhagen University Hospital).
For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com
This information was submitted for publication, through the agency of the contact person set out above, at 8.00 CEST on 23May 2022.
About Saniona
Saniona is a clinical-stage biopharmaceutical company with a mission to leverage its ion channel targeting expertise to discover, develop and deliver innovative rare disease treatments. The company's most advanced product candidate, Tesomet, has been progressed into mid-stage clinical trials for hypothalamic obesity and Prader-Willi syndrome, serious rare disorders characterized by severe weight gain, disturbances of metabolic functions and uncontrollable hunger. These clinical trials are voluntarily paused due to funding limitations and Saniona is actively exploring partnering opportunities. Saniona has developed a proprietary ion channel drug discovery engine anchored by IONBASE, a database of more than 130,000 compounds, of which more than 20,000 are Saniona's proprietary ion channel modulators. Through its ion channel expertise, Saniona is advancing two wholly owned ion channel modulators, SAN711 and SAN903. SAN711 is in a Phase 1 clinical trial and is positioned for the treatment of neuropathic pain conditions, and SAN903 is in preclinical development for rare inflammatory, fibrotic and hematological disorders. Saniona is based in the Copenhagen area, Denmark, and is listed on Nasdaq Stockholm Small Cap.
Attachment
- 20220523 HO data in European Journal of Endocrinology (UK) (https://ml-eu.globenewswire.com/Resource/Download/97b4a866-6b84-4765-8b83-912ccb22788c)
